September 10, 2025Meditsinskiy sovet = Medical CouncilOpen Access

A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination

View Full Paper

Ask AI

Bookmark

A complete response was registered after 42 months of therapy with atezolizumab and bevacizumab.
The median overall survival was significantly higher at 19.2 months for the combination therapy compared to 13.4 months with sorafenib.
Patients receiving the atezolizumab and bevacizumab combination therapy experienced minimal adverse events and satisfactory tolerability.
The clinical observation contributes to the growing experience with combined immunooncologic and targeted drugs for HCC treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical observation reports notable improvements in outcomes for unresectable HCC patients receiving atezolizumab and bevacizumab, suggesting effective long-term therapeutic strategy.

Cite This Study

Menshikov et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64793dcd https://doi.org/10.21518/ms2025-256

View Full Paper

Ask AI

Bookmark

Implication

Clinical observation reports notable improvements in outcomes for unresectable HCC patients receiving atezolizumab and bevacizumab, suggesting effective long-term therapeutic strategy.

A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination

Key Points

Discussion

Implication

Cite This Study

A case of long-term therapy of hepatocellular carcinoma with atezolizumab and bevacizumab combination

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading